Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease

D’Incà, R.; Annese, Vito; Leo, Vincenza Di; Latiano, Anna; Quaino, V.; Abazia, C.; Vettorato, Maria Grazia; Sturniolo, G.C.

doi:10.1111/j.1365-2036.2006.02916.x

Cited by 89 publications

(58 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there was no correlation of IP with age, duration, activity of the disease and D-xylose absorption. Thirty three to 68% patients with CD have been reported to have increased IP using a variety of marker probes such as polyethylene glycol (PEG) 400, PEG 1000, 51 CrEDTA, 99m TcDTPA, 51 CrEDTA/ 14 C-mannitol, lactulose, mannitol, rhamnose and cellobiose [21][22][23][24] . In this study, we used lactulose and mannitol (L/M) excretion to quantify IP.…”

Section: Discussionmentioning

confidence: 99%

Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease

Benjamin¹,

Makharia²,

Ahuja³

et al. 2008

WJG

View full text Add to dashboard Cite

INTRODUCTIONIntestinal permeability (IP) is the property of the intestinal epithelium which refers to the facility with which it allows molecules to pass through by non-mediated diffusion [1] . IP has been implicated in the pathogenesis and frequent relapses of Crohn's disease (CD) [2][3][4][5][6] . Seven to 18% higher relapse rate has been reported in patients with increased IP compared to those with normal IP [7][8][9][10][11] . Moreover, RAPID COMMUNICATIONIntestinal permeability and its association with the patient and disease characteristics in Crohn's disease Abstract AIM: To assess the intestinal permeability (IP) in patients with Crohn's disease (CD) and study the association of IP with the patient and disease characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease

Benjamin¹,

Makharia²,

Ahuja³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…7 Interestingly, abnormal permeability of the small intestine in Crohn's disease seems also to be associated with CARD15 mutations. 9 However the genetic defect alone is not sufficient to induce the disease. Other factors are discussed to explain the barrier dysfunction in CD which include the abnormal composition of the luminal bacterial flora, the altered secretion of antimicrobial peptides and unknown external factors.…”

Section: Introductionmentioning

confidence: 99%

Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease

Noth

Stüber

Häsler

et al. 2012

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and aims: Intestinal barrier function in Crohn's disease patients and their first degree healthy relatives is impaired. The increased intestinal permeability may result in an enhanced mucosal immune response and thereby aggravate intestinal inflammation. Humanised anti-TNF-α antibodies have been shown to be effective in the treatment of active Crohn's disease and in the treatment of entero-cutaneous fistula. The aim of the present study was to investigate the influence of anti-TNF-α antibody (infliximab) treatment on the intestinal barrier function of patients with active Crohn's disease. Methods: The differential intestinal uptake of lactulose and mannitol was measured to quantify intestinal permeability in patients with long standing active Crohn's disease (n = 17) directly before and seven days after treatment with infliximab (5 mg/kg bodyweight). In parallel, intestinal permeability was studied in a healthy control group (n = 20). Serum samples were analysed with pulsed amperometric detection after separation on an anion exchange column. Results: Intestinal permeability was significantly increased in all patients with Crohn's disease (L/M ratio 0.24 ± 0.17) prior to infliximab treatment compared to the control group (L/M ratio 0.01 ± 0.02; p-value b 1 × 10 − 7 ). Treatment of patients with infliximab resulted in a marked decrease of intestinal permeability as measured by L/M ratio from 0.24 ± 0.17 before to 0.02 ± 0.02 (p-value b 1 × 10 − 7 ) seven days after infliximab application.Conclusions: Treatment with anti-TNF-α antibodies improved impaired intestinal barrier function in patients with Crohn's disease. This effect may correlate to the well documented antiinflammatory effect of TNF-α blockade in this intestinal disease.

show abstract

“…In addition, a group of investigators were able to demonstrate an increase in intestinal permeability before the onset of the Crohn's disease in a subject with increased familial risk of the disease [10]. The increase in permeability in the relatives of patients with familial Crohn's has also been shown to be accentuated in the relatives with NOD-2 mutations [8,11] and to be reversible with anti-TNF alpha therapy [12]. Fig.…”

Section: Dr Daniel Hollandermentioning

confidence: 99%

Intestinal Permeability Barrier in Crohn’s Disease: The Difficulty in Shifting the Paradigm

Hollander

2013

Dig Dis Sci

View full text Add to dashboard Cite

Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease

Abstract: SUMMARY BackgroundAbnormal barrier function may be genetically determined in Crohn's disease.

Cited by 89 publications

References 32 publications

Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease

Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease

Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease

Intestinal Permeability Barrier in Crohn’s Disease: The Difficulty in Shifting the Paradigm

Contact Info

Product

Resources

About